Neurotech International Ltd Total Assets
Neurotech International Ltd total assets. Based on the latest financial reports, Neurotech International Ltd (NTI) holds total assets worth AU$2.75 Million AUD (≈ $1.94 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Neurotech International Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Neurotech International Ltd (2015–2026)
Total assets of Neurotech International Ltd from 2015 to 2026. This chart illustrates how Neurotech International Ltd's total assets have evolved over time, based on quarterly financial data. See Neurotech International Ltd share price for real-time trading data and today's change.
Neurotech International Ltd - Asset Composition Analysis
Neurotech International Ltd Total Assets Breakdown (June 2026)
Neurotech International Ltd total assets breakdown as of June 2026. Neurotech International Ltd's total assets of AU$2.75 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 86.9% |
| Accounts Receivable | AU$342.34K | 12.5% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2015–2026)
This chart illustrates how Neurotech International Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Neurotech International Ltd (NTI) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurotech International Ltd's current assets represent 100.0% of total assets in 2026, an increase from 64.5% in 2015.
- Cash Position: Cash and equivalents constituted 86.9% of total assets in 2026, up from 57.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 12.5% of total assets.
Neurotech International Ltd Competitors by Total Assets
Key competitors of Neurotech International Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Neurotech International Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 11.34 | 14.33 |
| Quick Ratio | 1.29 | 11.34 | 14.33 |
| Cash Ratio | 0.00 | 0.00 | 13.82 |
| Working Capital | AU$611.14K | AU$2.95 Million | AU$4.66 Million |
Neurotech International Ltd - Advanced Valuation Insights
This section examines the relationship between Neurotech International Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 34.38 |
| Latest Market Cap to Assets Ratio | 6.66 |
| Asset Growth Rate (YoY) | -15.2% |
| Total Assets | AU$2.75 Million |
| Market Capitalization | $18.30 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurotech International Ltd's assets at a significant premium (6.66x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neurotech International Ltd's assets decreased by 15.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurotech International Ltd (2015–2026)
The table below shows the annual total assets of Neurotech International Ltd from 2015 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | AU$2.75 Million ≈ $1.94 Million |
-15.21% |
| 2025-06-30 | AU$3.24 Million ≈ $2.29 Million |
-73.47% |
| 2024-06-30 | AU$12.21 Million ≈ $8.64 Million |
+130.06% |
| 2023-06-30 | AU$5.31 Million ≈ $3.76 Million |
+162.43% |
| 2022-06-30 | AU$2.02 Million ≈ $1.43 Million |
-59.59% |
| 2021-06-30 | AU$5.01 Million ≈ $3.54 Million |
+6095.02% |
| 2020-06-30 | AU$80.81K ≈ $57.17K |
-87.62% |
| 2019-06-30 | AU$652.75K ≈ $461.86K |
-85.83% |
| 2018-06-30 | AU$4.61 Million ≈ $3.26 Million |
-6.98% |
| 2017-06-30 | AU$4.95 Million ≈ $3.50 Million |
-67.79% |
| 2016-06-30 | AU$15.37 Million ≈ $10.88 Million |
+368.28% |
| 2015-12-31 | AU$3.28 Million ≈ $2.32 Million |
-- |
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute… Read more